Name | Number of supported studies | Average coverage | |
---|---|---|---|
natural killer cell | 5 studies | 21% ± 5% | |
epithelial cell | 5 studies | 24% ± 8% | |
CD16-negative, CD56-bright natural killer cell, human | 4 studies | 18% ± 2% | |
CD16-positive, CD56-dim natural killer cell, human | 4 studies | 24% ± 5% | |
endothelial cell | 3 studies | 18% ± 0% | |
GABAergic neuron | 3 studies | 36% ± 8% | |
glutamatergic neuron | 3 studies | 47% ± 11% | |
gamma-delta T cell | 3 studies | 20% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 100% | 1415.14 | 21 / 21 | 100% | 22.22 | 504 / 504 |
breast | 100% | 1563.21 | 459 / 459 | 100% | 26.08 | 1118 / 1118 |
esophagus | 100% | 1370.40 | 1445 / 1445 | 100% | 23.90 | 183 / 183 |
kidney | 100% | 1248.46 | 89 / 89 | 100% | 17.19 | 901 / 901 |
liver | 100% | 1184.05 | 226 / 226 | 100% | 19.61 | 406 / 406 |
ovary | 100% | 1667.78 | 180 / 180 | 100% | 25.73 | 430 / 430 |
pancreas | 100% | 798.78 | 328 / 328 | 100% | 16.49 | 178 / 178 |
prostate | 100% | 1561.37 | 245 / 245 | 100% | 20.21 | 502 / 502 |
stomach | 100% | 1198.96 | 359 / 359 | 100% | 22.70 | 286 / 286 |
thymus | 100% | 1510.25 | 653 / 653 | 100% | 18.46 | 605 / 605 |
uterus | 100% | 1519.37 | 170 / 170 | 100% | 25.01 | 459 / 459 |
brain | 100% | 1474.25 | 2639 / 2642 | 100% | 20.24 | 705 / 705 |
intestine | 100% | 1598.36 | 966 / 966 | 100% | 24.07 | 526 / 527 |
lung | 100% | 1164.99 | 576 / 578 | 100% | 21.89 | 1155 / 1155 |
adrenal gland | 100% | 1825.73 | 258 / 258 | 100% | 20.65 | 229 / 230 |
skin | 100% | 1817.81 | 1809 / 1809 | 99% | 21.17 | 469 / 472 |
adipose | 100% | 1519.00 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 24.80 | 29 / 29 |
muscle | 100% | 2007.18 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 1870.72 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 23.16 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 17.06 | 1 / 1 |
blood vessel | 100% | 1038.95 | 1333 / 1335 | 0% | 0 | 0 / 0 |
heart | 98% | 1385.20 | 848 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 94% | 17.52 | 75 / 80 |
peripheral blood | 84% | 945.20 | 778 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0032508 | Biological process | DNA duplex unwinding |
GO_0000965 | Biological process | mitochondrial RNA 3'-end processing |
GO_0030307 | Biological process | positive regulation of cell growth |
GO_2000827 | Biological process | mitochondrial RNA surveillance |
GO_0006401 | Biological process | RNA catabolic process |
GO_0000962 | Biological process | positive regulation of mitochondrial RNA catabolic process |
GO_0007005 | Biological process | mitochondrion organization |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0000958 | Biological process | mitochondrial mRNA catabolic process |
GO_0035946 | Biological process | mitochondrial mRNA surveillance |
GO_0000957 | Biological process | mitochondrial RNA catabolic process |
GO_0035945 | Biological process | mitochondrial ncRNA surveillance |
GO_0006310 | Biological process | DNA recombination |
GO_0045025 | Cellular component | mitochondrial degradosome |
GO_0042645 | Cellular component | mitochondrial nucleoid |
GO_0005739 | Cellular component | mitochondrion |
GO_0005759 | Cellular component | mitochondrial matrix |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0004386 | Molecular function | helicase activity |
GO_0003724 | Molecular function | RNA helicase activity |
GO_0034458 | Molecular function | 3'-5' RNA helicase activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0003678 | Molecular function | DNA helicase activity |
GO_0005524 | Molecular function | ATP binding |
GO_0003723 | Molecular function | RNA binding |
GO_0005515 | Molecular function | protein binding |
GO_0016887 | Molecular function | ATP hydrolysis activity |
GO_0003725 | Molecular function | double-stranded RNA binding |
Gene name | SUPV3L1 |
Protein name | Suv3 like RNA helicase ATP-dependent RNA helicase SUPV3L1, mitochondrial (EC 3.6.4.13) (Suppressor of var1 3-like protein 1) (SUV3-like protein 1) |
Synonyms | SUV3 |
Description | FUNCTION: Major helicase player in mitochondrial RNA metabolism. Component of the mitochondrial degradosome (mtEXO) complex, that degrades 3' overhang double-stranded RNA with a 3'-to-5' directionality in an ATP-dependent manner. Involved in the degradation of non-coding mitochondrial transcripts (MT-ncRNA) and tRNA-like molecules . ATPase and ATP-dependent multisubstrate helicase, able to unwind double-stranded (ds) DNA and RNA, and RNA/DNA heteroduplexes in the 5'-to-3' direction. Plays a role in the RNA surveillance system in mitochondria; regulates the stability of mature mRNAs, the removal of aberrantly formed mRNAs and the rapid degradation of non coding processing intermediates. Also implicated in recombination and chromatin maintenance pathways. May protect cells from apoptosis. Associates with mitochondrial DNA. . |
Accessions | B1AR60 Q8IYB8 ENST00000422378.1 ENST00000359655.9 |